The plaintiffs filed a motion in December 2023 to consolidate Ozempic lawsuits into a class-action lawsuit or multidistrict litigation (MDL) which occurred in early February, creating the official Ozempic lawsuit MDL 3094
IL-4 and IL-13 suppress the production of filaggrin, a structural protein critical for maintaining the stratum corneum
through the limited distribution network or wholesale acquisition process) for a given drug, to ensure appropriate support services
When healthy cells generate energy (adenosine triphosphate, or ATP) through the mitochondrial electron transport chain, they naturally produce highly reactive oxygen species (ROS) as a metabolic byproduct
7 Semaglutides role in the medical triad of diabetes, obesity, and cancer The prevalence of T2DM has increased significantly in the past decades
A flexible carbon nanotube based aqueous zinc ion hybrid micro-supercapacitor with wide voltage window